公司资料
Viatris Inc. 股价、新闻与催化剂
- 股票代码:
- VTRS
- 交易所:
- NASDAQ
- 行业:
- Generics, Small Molecule Drugs
- 所在地:
- United States
股票表现
16.23 USD (0.00%)
收盘价
最后更新: 2026年8月17日
18.3B USD
市值
股价为何变动
As of Aug 17, 2026, VTRS was little changed and closed at $16.23. No new same-company headline was identified in the current news window.
公司概览
业务概览
Viatris is a global healthcare company formed from the combination of Mylan and Pfizer’s Upjohn business. Its portfolio spans generics, branded generics, and some specialty products, with a business model centered on scale and portfolio management.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Viatris has a global commercial footprint. It sits in generics and diversified pharmaceuticals rather than biotech.
商业模式特征
The company generates value through product volume, geographic breadth, and lifecycle management across a broad medicines portfolio. Investors watch margin discipline, product mix, and the company’s ability to stabilize revenue after the merger integration.
生物医药行业定位
Viatris is outside biotech and closer to diversified pharma and generics. It matters to healthcare investors because its products are broadly used, but it is not a catalyst-heavy biotech stock.
未来催化剂
- Viatris’s near-term catalysts are biosimilar launches, portfolio simplification, and continued debt / capital-allocation progress. The next update will help show whether the company is moving from promise to a more de-risked stage of execution. Investors will care less about the label than about whether the platform can keep producing credible next steps.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。